Bisoprolol is generally referred to as Metoprolol Tartrate Tablets or Metoprolol Succinate Extended-Release Tablets, and there is no clinical statement as to which is safer, Bisoprolol Tablets or Metoprolol Tartrate Tablets or Metoprolol Succinate Extended-Release Tablets. Usually Bisoprolol tablets are mainly used for the treatment of coronary heart disease and high blood pressure. It is contraindicated for patients with sinus block, acute heart failure, severe bronchial asthma or severe chronic pulmonary obstruction, Raynaud’s syndrome, advanced peripheral arterial obstructive disease, second and third degree atrioventricular block and cardiogenic shock. Some patients may experience adverse reactions such as sweating, sleep abnormalities, excessive dreaming, mental disorders, visual disturbances, and muscle spasms after taking the drug. Metoprolol tartrate, for example, is mainly used in the clinic for the treatment of angina pectoris, myocardial infarction, hypertension, hyperthyroidism, arrhythmia and other diseases, and can also be used in the treatment of heart failure. The drug is contraindicated in patients with cardiogenic shock, sick sinus node syndrome, symptomatic bradycardia or hypotension, severe peripheral vascular disease with risk of gangrene, and atrioventricular block of II or III degree. Some patients may experience adverse reactions such as fatigue, headache, cold extremities, bradycardia, chest pain, weight gain, excessive sweating, hair loss, etc. Some patients may also exhibit thrombocytopenia, prolonged atrioventricular conduction time, depression, etc. After taking this drug. Patients are advised to use Bisoprolol Tablets and Metoprolol Tartrate Tablets or Metoprolol Succinate Extended-Release Tablets appropriately under medical supervision.